VCM
CRBP icon

Versant Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Versant Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.1K Hold
601
– – ﹤0.01% 2481
2026
Q2 		$5.64K Hold
601
– – ﹤0.01% 2411
2026
Q1 		$5.64K Hold
601
– – ﹤0.01% 2344
2025
Q4 		$4.89K Hold
601
– – ﹤0.01% 2260
2025
Q3 		$7.6K Hold
601
– – ﹤0.01% 2049
2025
Q2 		$4.15K Buy
+601
New +$4.37K ﹤0.01% 2217

Other funds holding CRBP

DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Versant Capital Management's CRBP Position: Q3 2026 in Review

Versant Capital Management held its Corbus Pharmaceuticals (CRBP) position steady in Q3 2026 at 601 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

Versant Capital Management first reported a position in CRBP in Q2 2025 and has held it in 6 quarters since. The position peaked at $7.6K in Q3 2025. 6 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

  • Versant Capital Management held 601 shares of Corbus Pharmaceuticals worth $4.1K as of Q3 2026.
  • Versant Capital Management left its Corbus Pharmaceuticals share count unchanged in Q3 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2481 holding.
  • Versant Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Versant Capital Management's Corbus Pharmaceuticals position peaked at $7.6K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.